Award
NIH Reporter #1ZIASC010372-25
Pre-clinical Development of Radiation Sensitizers for Patients with Glioblastoma
Recipient
DIVISION OF CLINICAL SCIENCES - NCI
Award Amount
$851,098.00
Ceiling
$851,098.00
Awarded
April 27, 2024
Identifier
1ZIASC010372-25
Award for pre-clinical development of radiation sensitizers targeting glioblastoma, focusing on KRAS and LSD1 pathways. In vitro work completed; animal studies pending due to restrictions.
Description
This year we have focused on two pathways. The first is the KRAS pathway. We initially determined if any of our GBM cell lines or glioma stem-cell lines had the common KRAS mutation. They did not. So we focused on drugs that inhibit the function of intact KRAS. The in vitro work for this study is complete but we are unable to complete the animal work due to new restrictions. The second study has focused on the use of an LSD1 inhibitor. Much like the KRAS study, we have finished the in vitro cell work but have not been able to complete the animal studies. When this gets fixed we should be able to complete both studies.